Neutralizing antibody evasion ability of adenovirus vector induced by the bioconjugation of methoxypolyethylene glycol succinimidyl propionate (MPEG-SPA).
暂无分享,去创建一个
Takao Hayakawa | Yasuo Tsutsumi | Tadanori Mayumi | Shinsaku Nakagawa | Yusuke Eto | Hiroyuki Mizuguchi | Jian-Qing Gao | Y. Tsutsumi | S. Nakagawa | T. Mayumi | H. Mizuguchi | T. Hayakawa | Jianqing Gao | K. Katayama | S. Kurachi | Kazufumi Katayama | Y. Eto | Fumiko Sekiguchi | Shinnosuke Kurachi | F. Sekiguchi
[1] P. Stewart,et al. A Helper-Independent Adenovirus Vector with E1, E3, and Fiber Deleted: Structure and Infectivity of Fiberless Particles , 1999, Journal of Virology.
[2] Y. Tsutsumi,et al. Antitumor effect by interleukin-11 receptor alpha-locus chemokine/CCL27, introduced into tumor cells through a recombinant adenovirus vector. , 2003, Cancer research.
[3] B. Trapnell,et al. Adenovirus-mediated gene transfer for cystic fibrosis: quantitative evaluation of repeated in vivo vector administration to the lung. , 1994, Gene therapy.
[4] E. Kominami,et al. Efficient Mitochondrial Import of Newly Synthesized Ornithine Transcarbamylase (OTC) and Correction of Secondary Metabolic Alterations in spfash Mice following Gene Therapy of OTC Deficiency , 1999, Molecular medicine.
[5] J. Maizel,et al. The polypeptides of adenovirus. I. Evidence for multiple protein components in the virion and a comparison of types 2, 7A, and 12. , 1974, Virology.
[6] M. Hitt,et al. Human adenovirus vectors for gene transfer into mammalian cells. , 1997, Advances in pharmacology.
[7] H. Mizuguchi,et al. Reduction of Natural Adenovirus Tropism to Mouse Liverby Fiber-Shaft Exchange in Combination with both CAR- andαv Integrin-BindingAblation , 2003, Journal of Virology.
[8] Y. Inada,et al. Biomedical and biotechnological applications of PEG- and PM-modified proteins. , 1995, Trends in biotechnology.
[9] B. Trapnell,et al. Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice , 1993, Nature Genetics.
[10] M. Bally,et al. Prevention of antibody-mediated elimination of ligand-targeted liposomes by using poly(ethylene glycol)-modified lipids. , 2002, The Journal of pharmacology and experimental therapeutics.
[11] B. Harvey,et al. "Sero-switch" adenovirus-mediated in vivo gene transfer: circumvention of anti-adenovirus humoral immune defenses against repeat adenovirus vector administration by changing the adenovirus serotype. , 1996, Human gene therapy.
[12] Y. Tsutsumi,et al. Molecular design of hybrid tumour necrosis factor-alpha. II: The molecular size of polyethylene glycol-modified tumour necrosis factor-alpha affects its anti-tumour potency. , 1996, British Journal of Cancer.
[13] J. Wilson,et al. Adenoviruses as gene-delivery vehicles. , 1996, The New England journal of medicine.
[14] Y. Tsutsumi,et al. Molecular design of hybrid tumor necrosis factor-alpha III: polyethylene glycol-modified tumor necrosis factor-alpha has markedly enhanced antitumor potency due to longer plasma half-life and higher tumor accumulation. , 1996, The Journal of pharmacology and experimental therapeutics.
[15] M. Chillón,et al. Adenovirus complexed with polyethylene glycol and cationic lipid is shielded from neutralizing antibodies in vitro , 1998, Gene Therapy.
[16] B. Trapnell,et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. , 1998, Blood.
[17] Ronald G. Crystal,et al. Transfer of Genes to Humans: Early Lessons and Obstacles to Success , 1995, Science.
[18] C. Wohlfart,et al. Neutralization of adenoviruses: kinetics, stoichiometry, and mechanisms , 1988, Journal of virology.